Hosted on MSN
GEO Q1 Earnings Call: Management Highlights Investment in Federal Detention Capacity, Near-Term Margin Pressure
Private corrections company GEO Group (NYSE:GEO) in Q1 CY2025, with sales flat year on year at $604.6 million. Next quarter’s revenue guidance of $620 million underwhelmed, coming in 5.2% below ...
ATLANTA, GA - May 8, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and solid tumor ...
GEO-CM04S1 demonstrated significantly enhanced T cell responses, specifically IFN-γ secretion and activation-induced markers (AIM+), compared to a matched cohort receiving an authorized mRNA vaccine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback